EVAH, a biotechnology company specializing in the development of biologicals, agreed to acquire four technologies in animal health from Elanco, an American pharmaceutical company that produces medicines and vaccinations for pets and livestock. Financial terms were not disclosed. "EVAH is focusing on bringing sustainable development of animal health to a new level. Leveraging our lab-to-market innovation experience from previous entrepreneurial success, we are now sourcing, acquiring and in-licensing molecules and technologies to develop into valuable products, in order to satisfy major unmet needs in animal health. We proactively sought out Elanco and are very proud to conclude these agreements today," Michel Fortin, EVAH CEO.